Special Report: 6 Reasons Why XPhyto Therapeutics Can Enhance Your Portfolio - (CSE:XPHY | OTC:XPHYF | FSE:4XT)

By Richard Mason


Biotechs are among the most profitable, highest-margin businesses on earth.

Huge biotech potential at XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT)

Biotechs are among the most profitable, highest-margin businesses on earth.


Exclusivity and first-mover advantage. Pure and simple.

Protected IP that no-one else can legally copy. Getting to market before your peers.

Exclusivity and timing breeds profit.

COVID-19 has made fortunes for retail investors, who have successfully picked biotechs developing vaccines, therapeutics, and tests before they explode into the public consciousness.

So how do you find the next big winner?

Take XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT) as an example.

C$150 million market cap.

Its stock price is strong, up 202% in 2020 and hitting all time highs this year. But it’s well under the radar. It’s no household name. Yet.

Want a comparison?

Wise investors will know GW Pharmaceuticals (NGM:GWPH).

This NASDAQ-listed company built a hugely successful drug development business from its medical research into cannabis.

Its intellectual property gave birth to international brands, patents and trademarked drugs only it could sell.

Its growth was phenomenal.

In 2013, GW Pharmaceuticals had a US$150 million market cap.


It’s worth over $4 billion.

Or what about Sona Nanotech (CSE:SONA)?

Read our EXCLUSIVE REPORT to uncover a biotech star in the making – XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT)

This nanotech life sciences company has been on an incredible run since February, as it took its core technology and applied it to a rapid-response Covid-19 test.

Trading in this stock started the year at 12 Canadian cents, only to rise to C$14.15 with a C$860 million market-cap in recent weeks.

Sona’s been so successful, in fact, that it is now preparing for a full NASDAQ listing, following the same path that GW Pharmaceuticals led the way on.

In both cases, this was all driven by the brainpower and innovation of talented teams of scientists.

XPhyto (CSE:XPHY | OTC:XPHYF | FSE:4XT) is now pursuing this proven model and is building a pipeline of remarkable projects with blockbuster potential.

Chief among these is the company’s latest ‘in the field’ testing kit to detect COVID-19 infected patients.

This ground-breaking development could be a game-changer in the struggle to return to normal life.

Just days ago, XPhyto (CSE:XPHY | OTC:XPHYF | FSE:4XT) confirmed its new RNA-based coronavirus prototype test exceeded expectations in initial evaluation.


And it’s a proprietary test.

With an exclusive partner: 3a.

RNA and DNA are the most important molecules in cell biology. DNA carries our genetic information. What makes us, us. RNA takes this information and helps to convert it into proteins, building the structure of the human body. Coronaviruses use viral RNA to highjack our own cellular machinery to build their own proteins and replicate themselves.

These pioneering German scientists — working closely with XPhyto’s (CSE:XPHY | OTC:XPHYF | FSE:4XT) labs — have developed a real-time, low-cost, simple oral screening test to detect COVID-19 and other coronaviruses.

It’s fast acting, and as easy to use as a pregnancy test.

It’s called a lateral flow assay, or LFA.

Despite the name, it’s very easy to use.

It gives a Yes or No answer on the spot. COVID-19 or not. Results appear in just 5 to 7 minutes. No need to ferry test tubes back and forth to a testing site and lab.

This superfast check has massive market potential. Frontline workers from medical and care professionals to retail, teachers, school staff and private employees. Anyone can use it.

Anyone, anytime, anywhere.

No specialist skills required. Highly deployable. No additional equipment needed.

CRUCIAL to avoid the Hammer and begin the Dance.

Swift, innovative development –XPhyto (CSE:XPHY | OTC:XPHYF | FSE:4XT) is at the forefront of ground-breaking research. Read our SPECIAL REPORT to learn more.


XPhyto (CSE:XPHY | OTC:XPHYF | FSE:4XTsigned up with 3a in April 2020.

The deal combines XPhyto’s proprietary thin-film drug delivery tech — originally developed for narcotics but repurposed to detect viruses — with leading-edge German scientific efficiency. And now since then, they’ve added even more proprietary pathogen testing technology.

Can we ever get back to normal?

Despite the signs, It IS possible. And the companies that make it happen will change the world.

XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT) is perhaps one of our best shots.

Exclusive tech. Proprietary tests. Fast-acting, simple, use anywhere.

Global demand.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by XPhyto Therapeutics to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and thirty thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.


valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.


In this article:

Author: Richard Mason

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter